.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
UBS
AstraZeneca
Chubb
Novartis
McKesson
Accenture
QuintilesIMS
Johnson and Johnson

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022527

« Back to Dashboard
NDA 022527 describes GILENYA, which is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are four patents protecting this drug and one Paragraph IV challenge. Additional details are available on the GILENYA profile page.

The generic ingredient in GILENYA is fingolimod. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fingolimod profile page.

Summary for 022527

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:4

Pharmacology for NDA: 022527

Suppliers and Packaging for NDA: 022527

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GILENYA
fingolimod
CAPSULE;ORAL 022527 NDA Novartis Pharmaceuticals Corporation 0078-0607 0078-0607-15 30 CAPSULE in 1 BOTTLE (0078-0607-15)
GILENYA
fingolimod
CAPSULE;ORAL 022527 NDA Novartis Pharmaceuticals Corporation 0078-0607 0078-0607-89 7 CAPSULE in 1 CARTON (0078-0607-89)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength0.5MG
Approval Date:Sep 21, 2010TE:RLD:Yes
Patent:► SubscribePatent Expiration:Feb 18, 2019Product Flag?Substance Flag?YDelist Request?
Patented Use:TREATMENT OF AUTOIMMUNE DISEASE
Patent:► SubscribePatent Expiration:Sep 23, 2017Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF AUTOIMMUNE DISEASE
Patent:► SubscribePatent Expiration:Mar 29, 2026Product Flag?Substance Flag?Delist Request?

Expired Orange Book Patents for NDA: 022527

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
GILENYA
fingolimod
CAPSULE;ORAL022527-001Sep 21, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
US Army
Covington
Mallinckrodt
Cantor Fitzgerald
Fuji
Novartis
McKesson
Express Scripts
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot